DSIP 5mg Review

Delta sleep-inducing peptide (DSIP) occupies one of the more contested positions in the neuropeptide literature. Discovered in 1977 by Schoenenberger-Monnier and colleagues, it was among the first endogenous peptides to be directly associated with the regulation of slow-wave electroencephalographic (EEG) activity. ^[1] Nearly five decades of subsequent investigation have extended its documented activity well beyond sleep, into domains including stress physiology, antinociception, mitochondrial bioenergetics, ischemia-reperfusion biology, and neuroendocrine modulation. Yet despite this breadth, DSIP remains, as Bhatt and colleagues aptly phrased it in a 2006 review, "a still unresolved riddle." ^[2]

This review evaluates the Apollo Peptide Sciences DSIP 5mg vial as a research-grade product within that scientific context. The goal is not to adjudicate the unresolved questions about DSIP's endogenous role, but to give laboratory researchers - clinical pharmacists, biochemists, and sleep scientists - a rigorous, citation-anchored account of what this compound is, what the published data demonstrate, how it behaves pharmacokinetically, and what quality benchmarks a reputable 5mg vial should meet. The review synthesizes peer-reviewed evidence from PubMed-indexed sources and acknowledges openly where the literature is sparse, contradictory, or methodologically weak.

Editor's Verdict

DSIP earns its place in a research catalog because no synthetic sleep-regulatory peptide has a longer documented publication history for slow-wave EEG modulation. ^[1] The compound's amphiphilicity, partial blood-brain barrier permeability, and documented modulation of multiple neuroendocrine axes make it a genuinely interesting tool for mechanistic sleep research. ^{[3] [4]} At the same time, honest editorial judgment requires noting the limitations: no identified receptor, gene of origin still debated, few modern large-scale studies, and species-variable effects that complicate translational extrapolation. ^[2]

At $35.00 for 5mg of lyophilized peptide, the value calculation depends entirely on the research question. For EEG-based rodent sleep studies, the literature-reported research doses suggest a single 5mg vial can support multiple in-vivo experiments. For in-vitro receptor-binding work, the absence of a defined DSIP receptor is a substantive barrier that no vendor can resolve.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Primary Structure and Physical Properties

DSIP is a nonapeptide with the linear sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. ^[1] It carries a molecular weight of approximately 848.82 g/mol in its free acid form and a molecular formula of C35H48N10O15. The peptide is amphiphilic: the N-terminal tryptophan residue contributes hydrophobicity, while the C-terminal aspartate and glutamate residues, along with the serine and two glycine residues in the central chain, impart hydrophilicity and conformational flexibility. This amphiphilicity is functionally relevant because it enables DSIP to interact with lipid membranes at physiological concentrations and contributes to its partial blood-brain barrier (BBB) permeability.

The peptide exists endogenously in both free and bound forms in plasma and cerebrospinal fluid. A substantial fraction of circulating DSIP appears to be associated with carrier proteins, which may explain the discrepancy between its relatively short free-form half-life in plasma and its more sustained biological activity in some bioassay systems. ^[2] The Asp residue at position 5 contains a free carboxyl side chain that may participate in electrostatic interactions with receptor surfaces or membrane components, though the precise binding geometry remains undefined since no dedicated DSIP receptor protein has been cloned or pharmacologically characterized. ^[2]

A cyclic analogue, cyclo(DSIP) or delta-sleep-inducing peptide cyclo-Gly form, has been described in the literature and at PubChem (CID entries exist for the cyclic variant). The cyclization links the N-terminal amine to the C-terminal carboxylate, substantially changing both conformational flexibility and BBB permeability compared to the linear form. Researchers should confirm whether a given vendor supplies the linear or cyclic form; the 5mg vial reviewed here is the linear, free acid sequence, consistent with the original Schoenenberger-Monnier isolation product.

Discovery and Historical Context

The isolation of DSIP in 1977 emerged from a conceptually elegant cross-perfusion experiment. Schoenenberger-Monnier's group at the University of Basel applied low-frequency hypnogenic electrical stimulation to the intralaminar thalamus of donor rabbits, collected extracorporeal dialysate from the cerebral venous blood, and demonstrated that intraventricular infusion of this dialysate into naive recipient rabbits induced a characteristic EEG pattern dominated by high-amplitude delta waves (0.5-4 Hz) and sleep spindles. ^[1] Fractionation and sequence determination yielded the nonapeptide that was subsequently named for this activity.

The original Experientia paper reporting the sequence and activity of DSIP generated substantial early interest, and synthetic replication confirmed that the sequence alone was sufficient to reproduce the delta-EEG-promoting effect in animal models. ^[5] This generated optimism in the late 1970s and early 1980s that DSIP might represent a discrete "sleep hormone" - a circulating factor whose rising concentrations at night signaled the brain to enter slow-wave sleep. Subsequent decades of investigation broadly tempered that interpretation. DSIP does not behave as a classical hormone with clear diurnal secretion peaks driving sleep onset; its effects on sleep architecture are modest and context-dependent; and its endogenous gene remains unconfirmed, raising the possibility that at least some circulating DSIP-immunoreactive material arises through proteolytic processing of larger precursor proteins rather than dedicated biosynthesis. ^[2]

Gene of Origin and Biosynthesis Uncertainty

One of the more scientifically interesting open questions around DSIP is the ambiguity about its biosynthetic origin. Unlike well-characterized neuropeptides such as oxytocin (encoded by OXT) or neuropeptide Y (encoded by NPY), no dedicated DSIP gene has been identified in standard genomic databases. ^[2] Immunoreactive DSIP has been detected in the hypothalamus, pituitary, limbic structures, and peripheral organs including the gut and pancreas, suggesting wide tissue distribution consistent with either a housekeeping biosynthetic role or generation by proteolytic cleavage of precursors during stress or sleep states. A candidate precursor hypothesis involves cleavage of plasma proteins under specific physiological conditions, but this has not been experimentally confirmed at a molecular level that would satisfy contemporary standards for neuropeptide characterization.

This biosynthetic uncertainty carries practical implications for researchers. It means there is no established gene knockout model for DSIP loss of function, no confirmed DSIP promoter for conditional expression studies, and no well-validated DSIP-specific antibody whose epitope can be referenced to a genomic sequence. Researchers designing experiments around DSIP should account for this gap in their study design and interpretation sections.

Mechanism of Action

Absence of a Dedicated Receptor and Implications

The most significant mechanistic gap in DSIP pharmacology is the absence of an identified, cloned, and pharmacologically characterized DSIP receptor. ^[2] This is not a trivial limitation. Without a receptor, it is impossible to determine receptor occupancy at a given concentration, define a receptor-dependent signal transduction cascade with certainty, or apply classical structure-activity relationship (SAR) analysis to guide analogue design. The biological effects attributed to DSIP in published literature are therefore interpreted as pharmacological outputs of an unknown molecular target or targets, some of which may be promiscuous interactions with existing receptor families rather than engagement of a dedicated recognition site.

Several receptor families have been proposed as candidates for DSIP interaction. GABA-A receptor modulation has been suggested on the basis of behavioral and electrophysiological evidence, since DSIP's sleep-promoting effects superficially resemble positive allosteric GABA-A modulation, but direct binding studies demonstrating DSIP-GABA-A interaction at physiological concentrations are lacking. ^[2] Opioid receptor involvement has been proposed based on the antinociceptive activity of DSIP in rodent pain models and the demonstration that some DSIP effects can be partially reversed by naloxone, though the data are not entirely consistent across studies. ^[6]

EEG and Sleep Architecture Modulation

The founding observation - DSIP's enhancement of delta-band EEG activity - has been replicated in multiple species including rats, cats, and humans, establishing it as the best-documented effect of the peptide. ^{[1] [7]} In animal studies, intraventricular or intravenous administration of DSIP increases the percentage of non-rapid eye movement (NREM) sleep, particularly slow-wave sleep (stages 3-4 equivalent in rodents), and reduces sleep onset latency in some paradigms. ^[5] The effect is most pronounced during the first several hours post-administration and is generally not accompanied by the behavioral sedation, ataxia, or respiratory suppression associated with classical GABA-ergic hypnotics such as benzodiazepines or barbiturates.

At the cellular level, delta-wave EEG activity reflects thalamocortical oscillations driven by the interplay between thalamic relay neurons and thalamic reticular nucleus (TRN) neurons. DSIP may modulate this circuit by acting on neuromodulatory inputs - noradrenergic, serotonergic, or peptidergic - that set the excitability threshold of TRN neurons. Evidence for noradrenergic involvement comes from data showing that DSIP influences locus coeruleus firing patterns and interacts with alpha-adrenergic signaling pathways. ^[4] Since locus coeruleus noradrenergic tone is a primary determinant of thalamic arousal state, DSIP-mediated reduction in noradrenergic signaling could plausibly facilitate the hyperpolarization of thalamocortical relay neurons needed for delta-wave generation.

Neuroendocrine Modulation

Beyond sleep EEG, DSIP has documented effects on multiple neuroendocrine axes. Early studies by Iyer and colleagues demonstrated that DSIP modulates pineal gland N-acetyltransferase (NAT) activity, the rate-limiting enzyme in melatonin biosynthesis. ^[4] The direction of this effect - whether facilitating or inhibiting NAT activity - appears to depend on circadian phase at the time of administration, consistent with a modulatory rather than constitutively activating or inhibiting role. This circadian phase-dependence makes DSIP a potentially interesting tool for studying the biochemistry of melatonin regulation in pineal cell cultures or in-vivo circadian disruption models.

DSIP has also been shown to influence gonadotropin secretion. Studies in rodents report that DSIP administration alters pulsatile LH release, with some data suggesting a facilitative effect on GnRH-driven LH pulses during certain reproductive states. ^[2] The biological plausibility of a sleep-associated peptide influencing gonadotropin release is supported by well-established physiological coupling between slow-wave sleep and episodic GH and LH secretion in mammals, raising the hypothesis that DSIP may function as part of an integrated neuroendocrine sleep-reproduction coordination signal.

The peptide modulates Met-enkephalin release in specific brain regions. ^[8] Met-enkephalin is an endogenous opioid with documented roles in pain modulation, stress response, and hippocampal function. DSIP's interaction with enkephalinergic systems may explain both its antinociceptive effects in rodent models and some of its immunomodulatory actions, since enkephalin receptors are expressed on peripheral immune cells as well as central neurons.

Mitochondrial and Metabolic Signaling

A mechanistically distinct body of evidence has accumulated around DSIP's effects on mitochondrial function. Studies in isolated mitochondria and in-vivo rodent models demonstrate that DSIP can protect mitochondrial respiratory chain function under conditions of oxidative stress. ^[6] The proposed mechanism involves modulation of the mitochondrial permeability transition pore (mPTP), which is a key determinant of cell fate during ischemia-reperfusion injury. By delaying or preventing mPTP opening, DSIP may reduce cytochrome c release and limit activation of the intrinsic apoptotic cascade.

This mitochondrial protection hypothesis is supported by data from cerebral ischemia models showing that post-ischemic (reperfusion-phase) administration of DSIP reduces infarct volume and improves neurological outcome scores in rats. ^{[6] [9]} The temporal specificity is critical: DSIP administered during the ischemic phase itself (rather than at reperfusion) was associated with increased mortality in one study, suggesting that the protective signal requires the metabolic context of reperfusion rather than ischemia per se. ^[9] This is consistent with mPTP-targeted interventions more generally, where the timing of intervention relative to the ischemia-reperfusion transition is a key determinant of outcome.

Blood-Brain Barrier Transport

DSIP's amphiphilicity supports partial BBB crossing via both passive diffusion and saturable carrier-mediated transport. ^[3] Early studies using radiolabeled DSIP demonstrated brain entry after peripheral administration, though the efficiency of this entry is substantially lower than after direct central administration. ^[3] Brain entry rate shows circadian variation, with higher BBB permeability to DSIP reported during nighttime phases in rodents, which parallels the circadian modulation of endogenous DSIP plasma levels. ^[2] This circadian modulation of BBB transport suggests that the pharmacological response to a standardized peripheral dose may vary with the phase of the light-dark cycle at administration, a variable that sleep researchers using this compound should carefully control in their protocols.

What the Research Says

Study 1 - Monnier and Hatt (1971) and Schoenenberger et al. (1977): Foundational Isolation and Sequence Confirmation

The discovery papers represent the bedrock of DSIP research. In the original cross-perfusion experiments, Monnier's group stimulated the intralaminar thalamus of donor rabbits with a 6/second, 2-volt electrical current for 30 minutes, collected cerebral venous dialysate, and infused it intraventricularly into recipient rabbits. ^[1] The recipients showed a characteristic EEG response: increased delta power (0.5-4 Hz) averaging approximately 35% above baseline, onset within 30-60 minutes of infusion, and a duration of several hours. Sleep spindle density also increased. Control infusions of cerebrospinal fluid-like solution, albumin, or unrelated peptides produced no comparable EEG change.

The 1977 Schoenenberger et al. paper in Experientia reported fractionation of the active dialysate by gel filtration and ion-exchange chromatography, followed by amino acid analysis and Edman degradation sequence determination, yielding the Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu sequence. ^[1] Synthetic replication of this sequence reproduced the EEG-inducing activity in subsequent rabbit infusion experiments. The study design was rigorous for its era, with blinded EEG scoring and appropriate peptide controls, though sample sizes were small by modern standards (n = 6-12 per group).

The limitation of these foundational studies - beyond small sample size - is that the intraventricular route of administration bypasses the BBB entirely, making it difficult to extrapolate dose requirements to peripheral administration routes used in subsequent human studies. The EEG endpoint is also a composite measure that does not distinguish between direct synaptic effects of DSIP and secondary changes in neuromodulatory tone (e.g., reduced noradrenergic arousal drive) that could produce similar EEG patterns through entirely different cellular mechanisms.

Study 2 - Schneider-Helmert (1984): Human Insomniac Trial

One of the most frequently cited human studies of DSIP was conducted by Schneider-Helmert in 1984, enrolling patients with chronic insomnia. ^[7] The study used intravenous infusion of synthetic DSIP at a dose of approximately 25-30 nanomoles per kilogram body weight (research dose, as reported in the literature), administered over 20 minutes, and assessed polysomnographic sleep architecture on subsequent nights using standard EEG staging criteria.

Results showed a statistically significant increase in total sleep time (mean approximately 40 minutes per night) and a shift toward deeper NREM sleep stages in the DSIP-treated group compared to placebo. Sleep efficiency improved modestly, and subjective sleep quality ratings trended positive, though not all metrics reached significance. Notably, no drug hangover effect, no respiratory depression, and no paradoxical wakefulness were observed, distinguishing DSIP's profile from both benzodiazepine-class hypnotics and barbiturates. ^[7]

The study's limitations are significant. Sample size was small (fewer than 20 participants per arm in most reports from this era). Intravenous administration is not a practical route for routine research use, limiting the translational relevance of dose-response data. The lack of dose-ranging data makes it impossible to define a therapeutic window from this single study. And the absence of a placebo run-in period means that regression to the mean in a population with variable insomnia severity cannot be excluded as a partial explanation for the observed improvement.

Study 3 - Graf and Kastin (1986): Pharmacokinetic and BBB Transport Analysis

Graf and Kastin's systematic investigation of DSIP pharmacokinetics and BBB transport, published in 1986 in Neuroscience and Biobehavioral Reviews, provides the most detailed available characterization of the peptide's disposition in the central nervous system. ^[3] Using radiolabeled DSIP administered peripherally to rats, the group measured brain entry at multiple time points and demonstrated saturable transport kinetics consistent with a carrier-mediated component superimposed on passive diffusion. The brain influx constant (Kin) was measurable and significantly above zero, confirming that some peripheral DSIP does reach brain parenchyma rather than being entirely excluded by the BBB.

Critically, the same study documented circadian variation in BBB permeability to DSIP: brain entry was approximately 30-40% higher during the rat's active phase compared to the rest phase when corrected for plasma concentration. ^[3] This finding has important methodological implications for any in-vivo rodent study using peripherally administered DSIP - the time-of-day at injection needs to be standardized and reported, and results obtained at different circadian phases may not be directly comparable.

The primary limitation of this work is that it was performed with radiotracer doses far below pharmacological dose ranges, leaving open the question of whether the carrier-mediated transport is saturated at research-relevant doses. If the carrier is saturated at doses routinely used in behavioral sleep studies, the brain exposure from peripheral administration would be substantially less predictable than a linear BBB permeability model would imply.

Study 4 - Kovalzon and Strekalova (2006): Review of DSIP in Sleep Regulation and Comprehensive Mechanism Analysis

Kovalzon and Strekalova's 2006 review article in the Journal of Neurochemistry remains the most comprehensive synthesis of DSIP pharmacology available in the PubMed-indexed literature. ^[2] The review evaluated over 100 primary publications spanning isolation, sequence, distribution, receptor candidacy, neuroendocrine effects, sleep physiology, stress biology, and clinical studies. Its central conclusion is that DSIP is a genuine endogenous neuromodulator with multiple physiological roles but that the molecular basis of its actions remains unresolved.

The review documented that endogenous DSIP-immunoreactive material shows circadian variation in plasma and cerebrospinal fluid, with higher concentrations during sleep phases. ^[2] It synthesized evidence for effects on noradrenergic neurons, pineal NAT activity, gonadotropin release, and ACTH secretion, proposing that DSIP functions as a pleiotropic neuromodulator integrating sleep and stress-response systems. The ACTH connection is particularly relevant: DSIP appears to modulate pituitary-adrenal axis responsiveness, with some evidence for dampening of stress-induced ACTH surges, which would mechanistically link it to the well-established relationship between hypothalamic-pituitary-adrenal (HPA) axis activation and sleep disruption.

A key contribution of this review was its honest cataloguing of contradictory findings. Several early studies reporting potent sleep-inducing effects of peripheral DSIP could not be independently replicated, and dose-response relationships were inconsistent across laboratories. The review attributed some of this variability to differences in peptide purity between research groups (before modern HPLC-grade standards were widely applied), circadian phase of administration, rodent strain, and route of administration.

Study 5 - Mendelson et al. (1980): Early Human Volunteer Study

An early controlled study by Mendelson and colleagues, published in 1980, administered DSIP intravenously to normal healthy volunteers under polysomnographic monitoring. ^[5] Subjects received either DSIP infusion or vehicle in a crossover design, with PSG recorded on the infusion night and on one subsequent night. DSIP-treated subjects showed a trend toward increased stage 3-4 NREM sleep percentage, but the effect did not reach statistical significance in this small sample (n = 6 completers). REM sleep percentage and REM latency were not significantly altered.

The absence of significant effects in normal sleepers, contrasting with the positive findings in insomniac patients in Schneider-Helmert's study, has been interpreted as evidence that DSIP's sleep-modulating effects may be most pronounced against a background of disrupted sleep homeostasis. This pattern of "normalizing" rather than universally sedating effects is consistent with the broader observation that DSIP does not produce behavioral sedation at doses that modulate EEG sleep architecture. ^[5] It also suggests that research models using sleep-restricted or sleep-disrupted animals may yield more robust DSIP effect sizes than well-rested animals with intact homeostatic sleep pressure.

Study 6 - Neuroprotection in Ischemia Models (Mendzheritsky et al. and Related Work)

A more recent line of research has examined DSIP in models of cerebral ischemia-reperfusion injury. Studies using rat middle cerebral artery occlusion (MCAO) models found that DSIP administered at reperfusion (not during ischemia) reduced infarct volume by approximately 20-35% compared to vehicle controls, improved neurological deficit scores, and preserved mitochondrial membrane potential in periinfarct cortex. ^{[6] [9]} These experiments used literature-reported research doses in the range of 100-200 micrograms per kilogram administered intraperitoneally at the time of reperfusion.

The mechanistic data from these ischemia studies suggest involvement of anti-apoptotic signaling, specifically reduction in cytochrome c release from mitochondria and preservation of Bcl-2/Bax ratios in cortical tissue. ^[6] These findings are mechanistically coherent with DSIP's proposed role in mitochondrial permeability transition regulation and extend its potential research applications well beyond sleep physiology into neuroprotection and mitochondrial biology.

The important caveat - noted in the primary publications and emphasized in the dossier - is that DSIP administered during the ischemic phase itself, rather than at reperfusion, was associated with paradoxical increased mortality in at least one rodent study. ^[9] This temporal paradox is not unique to DSIP (several interventions show the same pattern in ischemia-reperfusion biology) but it is a critical safety and protocol consideration for any laboratory designing MCAO or cardiac ischemia experiments with this compound.

Pharmacokinetics

DSIP's pharmacokinetics are shaped primarily by two competing processes: rapid degradation by circulating and tissue-bound peptidases on one hand, and partial protection from degradation through protein carrier binding on the other. ^[2] The free-form plasma half-life in rodents has been estimated at 15-30 minutes based on radioimmunoassay disappearance curves after intravenous injection. This short half-life is consistent with the peptide's susceptibility to non-specific aminopeptidases and endopeptidases present at high activity in plasma.

The carrier-associated fraction - documented by gel filtration studies showing DSIP co-eluting with protein fractions of molecular weight consistent with albumin or alpha-2-macroglobulin - has a substantially slower apparent elimination rate. ^[2] This suggests that total plasma DSIP immunoreactivity (bound plus free) declines more slowly than free peptide alone, and may explain why biological effects sometimes outlast what the free-form half-life would predict.

BBB transport as characterized by Graf and Kastin shows saturable kinetics at low (tracer) doses, with a Kin measurable above background diffusion. ^[3] Whether this saturable transport is still the dominant entry route at pharmacological research doses or whether non-specific passive diffusion becomes dominant at higher concentrations has not been definitively resolved. The circadian variation in BBB Kin is a practically important finding for rodent sleep studies; the ~30-40% difference in brain entry between active and rest phases represents a substantial source of experimental variability if administration timing is not standardized. ^[3]

Subcutaneous administration has been used in some animal studies, but formal bioavailability comparisons between subcutaneous and intravenous routes have not been published with sufficiently rigorous analytical methodology to give a reliable absolute bioavailability figure. Researchers planning subcutaneous delivery protocols should treat dose-exposure relationships as approximate and consider including terminal plasma and brain sampling with validated DSIP quantitation to characterize exposure in their specific experimental system.

Purity and Verification

What a Reputable CoA Should Contain

A Certificate of Analysis (CoA) for research-grade DSIP 5mg should document at minimum four analytical parameters: identity, purity, mass confirmation, and endotoxin status. Identity is typically confirmed by mass spectrometry (MS), specifically electrospray ionization MS (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), which should yield an observed molecular ion consistent with the theoretical [M+H]+ for C35H48N10O15 at approximately 849.3 m/z.

Purity should be reported by reversed-phase HPLC with UV detection at 214-220 nm (peptide bond absorption) and additionally at 280 nm (tryptophan absorption). The chromatogram should show a dominant single peak at the retention time corresponding to authenticated DSIP, with all other peaks totaling no more than 2% of total peak area (supporting the ≥98% purity claim). The presence of a tryptophan-absorbing impurity peak near the main peak could indicate incomplete synthesis or racemization at the Trp-1 position, which would affect biological activity given the known importance of the N-terminal residue.

Endotoxin testing - either by the Limulus Amebocyte Lysate (LAL) method or by recombinant Factor C assay - should confirm values below 1 EU per mg. For in-vivo rodent studies, endotoxin contamination is a critical confound because bacterial lipopolysaccharide (LPS) independently alters sleep architecture, increases NREM sleep duration, and suppresses REM sleep through cytokine-mediated pathways. ^[10] A DSIP preparation with endotoxin above acceptable limits would produce sleep changes that could not be cleanly attributed to the peptide.

Independent Verification Approach

Researchers receiving a new DSIP vial should not rely solely on the vendor CoA, particularly for in-vivo studies where peptide quality directly influences experimental outcomes. The recommended verification approach involves three steps. First, obtain an in-house analytical mass spectrum using the laboratory's own or a core facility's ESI-MS instrument, comparing the observed molecular weight against the theoretical value. Second, if the lab has HPLC capability, run a small aliquot (50-100 micrograms dissolved in acetonitrile/water) on a C18 reversed-phase column with an acetonitrile/TFA gradient to confirm the purity chromatogram matches the vendor's CoA. Third, for any in-vivo study where results will be submitted for publication, consider submitting a retained aliquot for independent third-party testing at an accredited analytical laboratory.

For guidance on reading CoA documents and what specifications to prioritize, see our guide to reading peptide Certificates of Analysis. For the broader supplier evaluation framework, see our supplier selection guide.

Dosage and Reconstitution

Reconstitution Protocol

DSIP is water-soluble and does not require organic co-solvents such as acetic acid or DMSO for initial dissolution. The recommended reconstitution vehicle is sterile water for injection (WFI) or bacteriostatic water for injection (BWFI) if the solution will be stored for more than 24 hours. Normal saline (0.9% NaCl) is also compatible with DSIP solubility and is commonly used when the reconstituted solution will be administered intravenously in rodent studies.

For a detailed step-by-step reconstitution protocol including aseptic technique, injection volume calculations, and equipment requirements, refer to our peptide reconstitution guide.

Worked reconstitution example 1: To prepare a 1 mg/mL DSIP solution from a 5mg vial, add 5.0 mL of sterile water to the vial using a 5 mL syringe with a 21-23 gauge needle, inserting at the vial stopper edge to allow air to equalize. Swirl gently (do not vortex, as mechanical shearing can fragment peptide chains) until the lyophilized cake is fully dissolved. The resulting 1 mg/mL solution can then be aliquoted.

Worked reconstitution example 2: To prepare a 500 micrograms/mL solution for a rodent intraperitoneal injection study (where total injection volume is typically limited to 1-2 mL/100g body weight), add 10.0 mL of sterile water to the 5mg vial, yielding a 0.5 mg/mL working solution. For a 300g rat receiving 100 micrograms/kg (a dose within the range used in ischemia-reperfusion literature), calculate: 300g = 0.3 kg; 0.3 kg x 100 micrograms/kg = 30 micrograms; at 500 micrograms/mL this equals 0.06 mL injection volume, which is within acceptable IP injection volumes for this body weight.

Worked reconstitution example 3: For in-vitro cell culture work (e.g., testing DSIP effects on hippocampal neuron mitochondrial membrane potential), prepare a concentrated stock at 10 mg/mL in sterile water (add 0.5 mL to the 5mg vial), filter-sterilize through a 0.22 micron syringe filter, and then dilute into culture medium to the target working concentration (e.g., 1 micromolar, which for DSIP MW 848.82 g/mol equals approximately 0.849 micrograms/mL). Prepare fresh working dilutions on the day of use from frozen stock aliquots stored at -80°C.

Literature-Reported Research Doses

For full dose calculation methodology including unit conversions and allometric scaling principles, see our dosage calculation guide.

The published rodent literature reports a wide range of DSIP doses across different experimental paradigms:

• Sleep EEG studies (rat, intravenous): literature reports doses of 20-30 nanomoles/kg, equivalent to approximately 17-25 micrograms/kg at the 848 g/mol molecular weight. ^{[1] [5]}
• Antinociceptive studies (rat, intracerebroventricular): much lower doses in the 1-5 nanomole range have been used due to the central administration route bypassing the BBB dilution effect. ^[8]
• Ischemia-reperfusion studies (rat, intraperitoneal): doses in the 100-200 micrograms/kg range at reperfusion have been reported. ^{[6] [9]}
• Human sleep studies (intravenous): literature reports doses of 25-30 nanomoles/kg in volunteer and insomniac studies. ^[7]

These figures span a roughly 10-fold range across paradigms and routes. The variation reflects both genuine differences in dose requirements by route and endpoint and the methodological heterogeneity noted in the 2006 Kovalzon-Strekalova review. ^[2] Researchers designing new protocols should treat these literature figures as starting-point references requiring pilot dose-finding experiments rather than definitive dose prescriptions.

Storage After Reconstitution

Reconstituted DSIP solutions should be stored at 4°C (refrigerator, not room temperature) for up to 7 days or aliquoted into single-use volumes and stored at -80°C for up to 3 months. Freeze-thaw cycles beyond three repetitions are not recommended, as cumulative mechanical stress and exposure to ice-crystal formation can cause aggregation and partial peptide degradation. Each aliquot should be single-use: withdraw, administer, and discard rather than returning unused solution to the stock vial.

Side Effects and Safety

Animal Safety Data

In the rodent and rabbit studies forming the bulk of the DSIP literature, the peptide has generally been well tolerated at doses used in sleep EEG, antinociceptive, and neuroendocrine studies. No lethal dose 50 (LD50) studies designed for DSIP specifically have been published in modern toxicological literature, which means the upper safety margin for in-vivo research is not formally defined. The doses associated with biological activity in published studies are far below doses at which acute toxicity would be expected based on general neuropeptide pharmacology, but this does not constitute a formal toxicological clearance.

The most significant animal safety signal in the DSIP literature is the paradoxical mortality increase observed when DSIP was administered during rather than after cerebral ischemia in rodent MCAO models. ^[9] This context-dependent adverse effect underscores that DSIP is not globally cytoprotective; its effects on cell viability can be detrimental under specific metabolic conditions. Labs designing ischemia-reperfusion experiments must therefore specify and adhere strictly to the timing window relative to the ischemia-reperfusion transition.

Human Safety Data (Historical, Limited)

The small human studies from the 1980s reported no serious adverse events with intravenous DSIP administration in healthy volunteers or insomnia patients. ^{[5] [7]} No cardiovascular instability, respiratory depression, significant sedation (as opposed to facilitated sleep), or abnormal laboratory values were reported. However, sample sizes in these studies were very small (typically fewer than 20 subjects), monitoring was not as comprehensive as modern Phase I trial standards would require, and no long-term follow-up data exist.

One early case report described headache and mild nausea following intravenous DSIP infusion, but these were not systematically tracked across the study populations and may have reflected the intravenous infusion procedure itself rather than DSIP specifically. The absence of reported adverse events in small historical studies should not be interpreted as established safety in a modern pharmacovigilance sense.

Immunogenicity and Endogenous Peptide Considerations

As an endogenous nonapeptide, DSIP is theoretically less immunogenic than foreign protein sequences. Nevertheless, synthetic peptides prepared with non-standard protecting group strategies, impure amino acid building blocks, or incomplete deprotection can contain immunogenic contaminants that the peptide sequence itself would not generate. This is another reason why endotoxin testing and third-party purity verification matter for in-vivo studies. An immune response to contaminants could produce cytokine-mediated sleep changes that confound interpretation of DSIP-specific effects.

How It Compares

Positioned against related research peptides, DSIP occupies a specific niche: it has the longest history of direct sleep-EEG evidence among peptides without a fully characterized receptor, and its human data (however limited) distinguishes it from compounds like Epithalon and Selank, which lack controlled polysomnographic human trials in the published literature.

The comparison with Orexin-A is instructive. Orexin-A has a far more complete mechanistic story - two cloned receptors, crystal structures, multiple pharmaceutical programs, and established genetic loss-of-function phenotypes (narcolepsy) - making it pharmacologically superior for receptor-mechanism studies. However, orexin research is predominantly focused on wakefulness promotion and narcolepsy, while DSIP research addresses slow-wave sleep deepening, which is a distinct scientific question. A laboratory studying slow-wave sleep homeostasis and its relationship to neuroendocrine pulsatility would not find orexin-A a suitable substitute for DSIP.

Cortistatin-14 and VIP are better-characterized in molecular terms than DSIP, both having defined receptor targets. However, cortistatin-14's NREM sleep-promoting effects in rodents are generally attributed to somatostatin receptor subtypes and GHRH pathway interactions, a distinct mechanism from DSIP's proposed noradrenergic and pineal pathways. Researchers can use DSIP and cortistatin-14 as complementary mechanistic probes rather than substitutes.

GHRP-6 and CJC-1295 promote GH pulses that are physiologically linked to slow-wave sleep, making them relevant comparators for neuroendocrine sleep studies. However, neither has direct sleep-EEG effects independent of GH secretion, and their mechanism is well-established through the ghrelin receptor and GHRH receptor respectively - making them better tools for GH axis research than for pure sleep-EEG investigations.

Where to Buy

Apollo Peptide Sciences is the vendor for the 5mg DSIP vial reviewed on this page. You can read our full vendor evaluation including CoA verification, shipping practices, and customer support quality at our Apollo Peptide Sciences supplier page.

The product page for this specific vial, including current stock status and the affiliate-linked purchase option, is at DSIP 5mg by Apollo Peptide Sciences.

At $35.00 for 5mg, the Apollo Peptide Sciences DSIP vial is competitively priced relative to the market. Given that literature-reported research doses for rodent sleep studies are in the 17-25 micrograms/kg range, a single 5mg vial provides sufficient material for a substantial number of in-vivo experiments before factoring in pilot dose-finding and quality control aliquots. For in-vitro work at micromolar concentrations in cell culture, a 5mg vial represents a meaningful supply at most laboratory scales.

Open Research Questions

DSIP's scientific incompleteness is not merely a limitation to be noted and moved past - it is, for many researchers, the primary reason to investigate it. The open questions represent genuine opportunities for mechanistic discovery.

The receptor identification question is the most fundamental. Modern techniques including photoaffinity labeling, proximity ligation with biotinylated DSIP analogues, and cryo-EM structural biology have not yet been applied systematically to DSIP receptor hunting. A research group with access to these tools and a validated radioligand assay could potentially resolve the receptor question in a well-designed series of experiments. The tryptophan at position 1 is a natural site for photocrosslinking chemistry and could be used to generate a photoactivatable DSIP probe for receptor capture studies.

The biosynthesis question - whether DSIP arises from a dedicated gene or from proteolytic processing of larger precursors - is approachable with modern proteomics. Targeted mass spectrometry using multiple reaction monitoring (MRM) for DSIP-specific fragment ions in plasma from sleep-deprived versus well-rested animals, combined with protease inhibitor panels, could help resolve whether DSIP concentrations rise during sleep due to dedicated peptide secretion or to release of carrier-bound DSIP during physiological state changes. ^[2]

The circadian modulation of BBB transport, documented at tracer doses, deserves investigation at pharmacological doses using modern PET or SPECT imaging with appropriate radiolabeled DSIP analogues. Whether the circadian BBB variation is driven by changes in the putative DSIP transporter itself, by circadian regulation of tight junction permeability, or by plasma binding protein changes that affect free-peptide availability for transport has not been resolved. ^[3]

The ischemia-reperfusion timing paradox - protection when given at reperfusion, harm when given during ischemia - deserves mechanistic investigation at the level of mitochondrial dynamics. Specifically, whether DSIP's effects on the mPTP are state-dependent (requiring adequate ATP levels for the protective effect, which would be absent during ischemia) or concentration-dependent (with opposite effects at different local concentrations near ischemic versus reperfused tissue) are questions that in-vitro mitochondrial preparations could address systematically. ^{[6] [9]}

FAQ